Search This Blog

Tuesday, January 21, 2020

Aldeyra commences late-stage study of reproxalap in allergic conjunctivitis

Enrollment is underway in a Phase 3 clinical trial, INVIGORATE, evaluating Aldeyra Therapeutics’ (NASDAQ:ALDX) topical ocular reproxalap in patients with allergic conjunctivitis.
The primary endpoint of the 120-subject study is ocular itching score compared to vehicle (placebo). The estimated completion date is September.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)